Radiation as immunomodulator: Implications for dendritic cell-based immunotherapy

Radiation Research

Volumn 182, Issue 2, 2014, Pages 211-218

  Roses, Robert E ^a   Datta, Jashodeep ^a   Czerniecki, Brian J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 84905739456     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR13495.1     Document Type: Article

References (87)

1. Schreiber RD. Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun 2005; 5(Suppl 1):1.
2. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48. (Pubitemid 39094044)
3. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96. (Pubitemid 46697910)
4. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55:237-45. (Pubitemid 41683212)
5. Hashimoto C, Hudson KL, Anderson KV. The toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52:269-79.
6. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in drosophila adults. Cell 1996; 86:973-83. (Pubitemid 26336801)
7. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the drosophila toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7. (Pubitemid 27334820)
8. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annual Rev Immunol 2002; 20:197-216. (Pubitemid 34293424)
9. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001; 413:732-8. (Pubitemid 33009951)
10. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998; 282:2085-8. (Pubitemid 29001265)
11. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9. (Pubitemid 38314424)
12. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5. (Pubitemid 32015992)
13. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23:130-5. (Pubitemid 34178294)
14. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4. J Immunol 2002; 168:5233-9. (Pubitemid 34495991)
15. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511. (Pubitemid 38931765)
16. Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol 2007; 28:227-33. (Pubitemid 46654873)
17. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, et al. Rapid high efficiency sensitization of CD8\+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003; 171:2251-61. (Pubitemid 37025530)
18. Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, et al. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid-derived dendritic cells is mediated by IL-12 production. Surgery 2006; 140:170-8. (Pubitemid 44176060)
19. Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4\+ T cell responses in vitro. J Immunother 2007; 30:75-82. (Pubitemid 46052205)
20. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27:49-55. (Pubitemid 43083564)
21. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000; 68:6883-90. (Pubitemid 32463398)
22. Ambach A, Bonnekoh B, Nguyen M, Schon MP, Gollnick H. Imiquimod, a toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. Mol Immunol 2004; 40:1307-14. (Pubitemid 38456982)
23. Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998; 92:3730-6. (Pubitemid 28525200)
24. Kochling J, Konig-Merediz SA, Stripecke R, Buchwald D, Korte A, Von Einsiedel HG, et al. Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clin Cancer Res 2003; 9:3142-9. (Pubitemid 36993277)
25. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5:397-405.
26. Bourquin C, Schreiber S, Beck S, Hartmann G, Endres S. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer 2006; 118:2790-5. (Pubitemid 43673358)
27. Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007; 67:1823-31. (Pubitemid 46383409)
28. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184-94. (Pubitemid 46718403)
29. Cole S. Long-term effects of local ionizing radiation treatment on Langerhans cells in mouse footpad epidermis. J Invest Dermatol 1986; 87:608-12. (Pubitemid 17178891)
30. James RF, Lake SP, Chamberlain J, Thirdborough S, Bassett PD, Mistry N, et al. Gamma irradiation of isolated rat islets pretransplantation produces indefinite allograft survival in cyclosporine-treated recipients. Transplantation 1989; 47:929-33. (Pubitemid 19161821)
31. Wasserman J, Blomgren H, Rotstein S, Petrini B, Hammarstrom S. Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bull N Y Acad Med 1989; 65:36-44. (Pubitemid 19065026)
32. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. A sense of danger from radiation. Radiat Res 2004; 162:1-19. (Pubitemid 39044714)
33. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 1989; 86:10104-7. (Pubitemid 20030785)
34. Ishihara H, Tanaka I, Nemoto K, Tsuneoka K, Cheeramakara C, Yoshida K, et al. Immediate-early, transient induction of the interleukin-1 beta gene in mouse spleen macrophages by ionizing radiation. J Radiat Res 1995; 36:112-24.
35. Nemoto K, Ishihara H, Tanaka I, Suzuki G, Tsuneoka K, Yoshida K, et al. Expression of IL-1 beta mRNA in mice after whole body X-irradiation. J Radiat Res 1995; 36:125-33.
36. Hong JH, Chiang CS, Tsao CY, Lin PY, McBride WH, Wu CJ. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 1999; 75:1421-7.
37. Cao MD, Chen ZD, Xing Y. Gamma irradiation of human dendritic cells influences proliferation and cytokine profile of T cells in autologous mixed lymphocyte reaction. Cell Biol Int 2004; 28:223-8. (Pubitemid 38230233)
38. Shigematsu A, Adachi Y, Koike-Kiriyama N, Suzuki Y, Iwasaki M, Koike Y, et al. Effects of low-dose irradiation on enhancement of immunity by dendritic cells. J Radiat Res 2007; 48:51-5. (Pubitemid 46219477)
39. Merrick A, Errington F, Milward K, O'Donnell D, Harrington K, Bateman A, et al. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer 2005; 92:1450-8. (Pubitemid 40705012)
40. Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immuno 2004; 173:2462-9. (Pubitemid 39063103)
41. Hashimoto S, Shirato H, Hosokawa M, Nishioka T, Kuramitsu Y, Matushita K, et al. The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats. Radiat Res 1999; 151:717-24. (Pubitemid 29252560)
42. Cao ZA, Daniel D, Hanahan D. Sub-lethal radiation enhances antitumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002; 2:11.
43. Ina Y, Sakai K. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: analysis of immune cell populations and surface molecules. Int J Radiat Biol 2005; 81:721-9. (Pubitemid 43200507)
44. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012; 2:153.
45. Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin Radiat Oncol 2013; 23:273-80.
46. El-Saghire H, Michaux A, Thierens H, Baatout S. Low doses of ionizing radiation induce immune-stimulatory responses in isolated human primary monocytes. Int J Mol Med 2013; 32:1407-14.
47. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-55. (Pubitemid 29535601)
48. Kim KW, Kim SH, Shin JG, Kim GS, Son YO, Park SW, et al. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer 2004; 109:685-90.
49. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9. (Pubitemid 47517504)
50. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8\+ T cells via TLR4 signaling. The J Clin Invest 2007; 117:2197-204. (Pubitemid 47219564)
51. Liu C, Zhang C, Mitchel RE, Cui J, Lin J, Yang Y, et al. A critical role of toll-like receptor 4 (TLR4) and its' in vivo ligands in basal radio-resistance. Cell Death Dis 2013; 4:e649.
52. Acker JC, Marks LB, Spencer DP, Yang W, Avery MA, Dodge RK, et al. Serial in vivo observations of cerebral vasculature after treatment with a large single fraction of radiation. Radiat Res 1998; 149:350-9. (Pubitemid 28150928)
53. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12:1539-46.
54. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191:423-34.
55. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003; 103:205-11. (Pubitemid 35461512)
56. Hauser SH, Calorini L, Wazer DE, Gattoni-Celli S. Radiationenhanced expression of major histocompatibility complex class I antigen H-2Db in B16 melanoma cells. Cancer Res 1993; 53:1952-5. (Pubitemid 23127130)
57. Hareyama M, Imai K, Kubo K, Takahashi H, Koshiba H, Hinoda Y, et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer 1991; 67:2269-74.
58. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170:6338-47. (Pubitemid 36682620)
59. Dunn PL, North RJ. Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cellmediated regression of immunogenic tumor. J Leukoc Biology 1991; 49:388-96.
60. North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med 1986; 164:1652-66. (Pubitemid 17184195)
61. Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 2007; 117:492-501. (Pubitemid 46203978)
62. Miller GM, Kim DW, Andres ML, Green LM, Gridley DS. Changes in the activation and reconstitution of lymphocytes resulting from total-body irradiation correlate with slowed tumor growth. Oncology 2003; 65:229-41. (Pubitemid 37505831)
63. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007; 204:49-55. (Pubitemid 46148755)
64. Hallahan DE, Staba-Hogan MJ, Virudachalam S, Kolchinsky A. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res 1998; 58:5216-20. (Pubitemid 28521185)
65. Hallahan DE, Virudachalam S. Accumulation of P-selectin in the lumen of irradiated blood vessels. Radiat Res 1999; 152:6-13. (Pubitemid 29296241)
66. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 2010; 107:8363-8.
67. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300:1155-9. (Pubitemid 36583102)
68. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120:694-705.
69. Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst 2012; 104:899-905.
70. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010; 70:5679-85.
71. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17:860-6.
72. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63:655-66. (Pubitemid 41400049)
73. Nikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 2001; 94:825-33. (Pubitemid 33032831)
74. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999; 59:6028-32. (Pubitemid 30035614)
75. Chakravarty PK, Guha C, Alfieri A, Beri V, Niazova Z, Deb NJ, et al. Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy. Oncology 2006; 70:245-54. (Pubitemid 44670164)
76. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58:862-70. (Pubitemid 38221143)
77. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated Tcell killing. Cancer Res 2004; 64:4328-37. (Pubitemid 38802440)
78. Chiang CS, Hong JH, Wu YC, McBride WH, Dougherty GJ. Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Ther 2000; 7:1172-8. (Pubitemid 30661035)
79. Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, et al. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol 1999; 15:769-73.
80. Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000; 2:195-203.
81. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54:4266-9. (Pubitemid 24273130)
82. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34. (Pubitemid 40116901)
83. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67:1842-52. (Pubitemid 46383411)
84. Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol 2013; 20:3233-9.
85. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11:361-9. (Pubitemid 40075816)
86. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004; 64:5074-7. (Pubitemid 39006521)
87. Yan L, Xu G, Qiao T, Chen W, Yuan S, Li X. CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of toll-like receptor 9. Cancer Biother Radiopharm 2013; 28:559-64.